Cocaine medications, cocaine consumption and societal costs
- PMID: 15344308
- DOI: 10.2165/00019053-200018040-00008
Cocaine medications, cocaine consumption and societal costs
Abstract
Objective: To estimate the benefits of reduced cocaine consumption in terms of reduced societal costs resulting from the introduction of a medication for cocaine dependence with a small incremental treatment effect.
Study design: Cost-benefit analysis is applied to study the implications of reduced cocaine consumption. A modelling approach extrapolates the magnitude of treatment effects.
Methods: Epidemiological data on cocaine use and consumption as well as economic methods of cost-benefit analysis are utilised. Estimates of societal costs associated with heavy users of cocaine, who are most likely addicted and in need of immediate treatment, are developed using 1995 data.
Main outcome measures and results: In the first analysis, a postulated 1% reduction in consumption of cocaine among heavy users is examined to approximate a small treatment effect, resulting in a minimal consumption benefit. It is estimated that such a reduction would be valued at $US259 million. The cost-benefit analysis indicated that a cocaine medication with a small treatment effect (10 percentage point increase in abstinence rates) would result in a benefit to cost ratio in the range of 1.58 to 5.79, depending on prescribing behaviour and type of patient.
Conclusions: Such estimates of the benefits of these small treatment effects are conservative, and they may be biased downwards since the willingness to pay for such a cocaine medication could far exceed the benefit to cost estimation used in this paper. Nevertheless, the substantial benefits found in this paper indicate how important investment in cocaine medication is for public health policy; costs may be reduced with efficient prescribing behaviour. Market and governmental barriers to the utilisation of a cocaine medication could reduce the benefits and increase costs. Clinical trials, cost-effectiveness studies, and cost-benefit studies must be conducted to establish the actual pattern of benefits and costs that could be obtained for an efficacious and effective cocaine medication.
Similar articles
-
Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.Pharmacoeconomics. 2004;22(14):929-42. doi: 10.2165/00019053-200422140-00003. Pharmacoeconomics. 2004. PMID: 15362929
-
Costs and benefits of treatment for cocaine addiction in DATOS.Drug Alcohol Depend. 1999 Dec 1;57(2):167-74. doi: 10.1016/s0376-8716(99)00083-6. Drug Alcohol Depend. 1999. PMID: 10617100
-
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.CNS Drugs. 2016 Feb;30(2):163-77. doi: 10.1007/s40263-016-0310-2. CNS Drugs. 2016. PMID: 26879458
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.Pharmacoeconomics. 2000 Jul;18(1):45-53. doi: 10.2165/00019053-200018010-00005. Pharmacoeconomics. 2000. PMID: 11010603 Review.
Cited by
-
Molecular, cellular, and structural mechanisms of cocaine addiction: a key role for microRNAs.Neuropsychopharmacology. 2013 Jan;38(1):198-211. doi: 10.1038/npp.2012.120. Epub 2012 Sep 12. Neuropsychopharmacology. 2013. PMID: 22968819 Free PMC article. Review.
-
Effect of cocaine on structural changes in brain: MRI volumetry using tensor-based morphometry.Drug Alcohol Depend. 2010 Oct 1;111(3):191-9. doi: 10.1016/j.drugalcdep.2010.04.012. Epub 2010 May 31. Drug Alcohol Depend. 2010. PMID: 20570057 Free PMC article.
-
Virtual reality cue-exposure therapy in reducing cocaine craving: the Promoting Innovative COgnitive behavioral therapy for Cocaine use disorder (PICOC) study protocol for a randomized controlled trial.Trials. 2024 Jun 27;25(1):421. doi: 10.1186/s13063-024-08275-7. Trials. 2024. PMID: 38937824 Free PMC article.
-
Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.J Med Chem. 2008 Jun 12;51(11):3322-5. doi: 10.1021/jm7013666. Epub 2008 May 8. J Med Chem. 2008. PMID: 18461921 Free PMC article.
-
Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors.Drug Alcohol Depend. 2012 May 1;122(3):220-7. doi: 10.1016/j.drugalcdep.2011.10.001. Epub 2011 Oct 24. Drug Alcohol Depend. 2012. PMID: 22030276 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical